Datametrex AI Limited
(TSXV:DM) (the
“
Company” or “
Datametrex”) is
pleased to announce its agreement to partner with EMPOWER CLINICS
INC. (
CSE: EPW) (“
Empower”)
through its subsidiary Canntop AI Inc. (“
Canntop”)
on the creation of a pilot program (“
Pilot”) using
Artificial Intelligence (“
AI”) to analyze and gain
insights about Empower patient data, physician treatment
recommendations and overall long-term efficacy of patient care.
This is to identify improvements and efficacy in long-term patient
care.
Empower intends to use Canntop’s AI platform to
gain actionable insights on how consumer social data is generating
nationwide interest in CBD based products, alternative pain
management options and the use of cannabis-based therapies.
The initial pilot will utilize Empower patient
data in a HIPAA compliant manner, to determine if normalized data
can be generated using Datametrex AI solutions to understand how
patient care and efficacy of physician guided treatment
recommendations are positively impacting serious qualifying
conditions of patients.
“We believe using AI tools to analyze the
substantial amounts of data in the Empower database and the
additional data from the recently announced proposed Sun Valley
acquisition can make Empower a data science leader in the Cannabis
industry,” said Steven McAuley, Empower’s Chairman & CEO. He
further states, “The outcomes of our AI efforts with Datametrex are
definitely going to position the Company as an educational leader
and we plan to collaborate with the industry to ultimately improve
patient care.”
“Datametrex has already utilized its Nexalogy AI
solution for Health Canada studies in the Cannabis sector to
understand consumer usage and patterns based on massive social
insights generated through social media channels,” said Jeffrey
Stevens, Datametrex President & COO. “We believe an AI pilot
with Empower has the potential to provide disruptive insights that
alternative care options can provide people around the world.”
ABOUT EMPOWER
Empower is undertaking new growth initiatives to
be positioned as a vertically integrated diverse health and
wellness company with an expanding network of physician-staffed
clinics, a diverse CBD product strategy and a leader in
hemp-derived CBD extraction, research and development. Treatment
solutions are focused on education, data and efficacy in
combination with other modalities to support patients with serious
qualifying conditions, such as chronic pain, PTSD, sleep disorders,
opioid dependency, epilepsy and more. It is expected that Empower's
proprietary product line “Sollievo” will offer patients a variety
of delivery methods of doctor recommended cannabidiol (CBD) based
product options in its clinics, online and at major retailers. With
over 120,000 patients, an expanding clinic footprint, a focus on
new technologies, including tele-medicine and an expanded product
development strategy, Empower is ready to capitalize on the
explosive growth expectations in the United States after the
passing of US$867 billion Agriculture Improvement Act (the Farm
Bill).
About Datametrex
Datametrex AI Limited is a technology focused
company with exposure to Artificial Intelligence and Machine
Learning through its wholly owned subsidiaries, Nexalogy
(www.nexalogy.com) and Canntop AI (www.canntop.com) and
Implementing Blockchain technology for secure Data Transfers
through its investee company, Graph Blockchain
(www.graphblockchain.com).
Additional information on Datametrex is
available at: www.datametrex.com
For further information, please
contact:
Jeffrey Stevens – President & COOPhone: (647) 400-8494Email:
jstevens@datametrex.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains "forward-looking
information" within the meaning of applicable securities
laws. All statements contained herein that are not clearly
historical in nature may constitute forward-looking information. In
some cases, forward-looking information can be identified by words
or phrases such as "may", "will", "expect", "likely", "should",
"would", "plan", "anticipate", "intend", "potential", "proposed",
"estimate", "believe" or the negative of these terms, or other
similar words, expressions and grammatical variations thereof, or
statements that certain events or conditions "may" or "will"
happen, or by discussions of strategy.
By their nature, forward-looking information is
subject to inherent risks and uncertainties that may be general or
specific and which give rise to the possibility that expectations,
forecasts, predictions, projections or conclusions will not prove
to be accurate, that assumptions may not be correct and that
objectives, strategic goals and priorities will not be achieved. A
variety of factors, including known and unknown risks, many of
which are beyond our control, could cause actual results to differ
materially from the forward-looking information in this press
release. Such factors include, without limitation, those discussed
in the Company's current MD&A and Annual Information Form, both
of which have been filed on SEDAR and can be accessed at
www.sedar.com.
Readers are cautioned to consider these and
other factors, uncertainties and potential events carefully and not
to put undue reliance on forward-looking information. The
forward-looking information contained herein is made as of the date
of this press release and is based on the beliefs, estimates,
expectations and opinions of management on the date such
forward-looking information is made. The Company undertakes no
obligation to update or revise any forward-looking information,
whether as a result of new information, estimates or opinions,
future events or results or otherwise or to explain any material
difference between subsequent actual events and such
forward-looking information, except as required by applicable
law.
DataMetrex AI (TSXV:DM)
Historical Stock Chart
From Mar 2024 to Apr 2024
DataMetrex AI (TSXV:DM)
Historical Stock Chart
From Apr 2023 to Apr 2024